Literature DB >> 6747647

Cerebrospinal fluid enolase in stroke.

E Hay, J A Royds, G A Davies-Jones, N A Lewtas, W R Timperley, C B Taylor.   

Abstract

This study relates the level of alpha and gamma enolase in cerebrospinal fluid sampled within 4 days of a stroke to the volume of the cerebral infarct measured on the CT image and to the clinical outcome of the patient. Twenty-eight patients were studied, two with transient ischaemic attacks and 26 with completed stroke due to infarction. The cerebrospinal fluid enolase was raised in the two patients with transient ischaemic attacks and 23 with completed stroke. There was a positive correlation between the volume of the infarct and the level of cerebrospinal fluid alpha and gamma enolase. A high cerebrospinal fluid enolase was always associated with a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6747647      PMCID: PMC1027902          DOI: 10.1136/jnnp.47.7.724

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  Glutamic-oxalacetic transaminase and lactic dehydrogenase in serum and cerebrospinal fluid of patients with neurologic disorders.

Authors:  G A FLEISHER; K G WAKIM; N P GOLDSTEIN
Journal:  Proc Staff Meet Mayo Clin       Date:  1957-04-17

2.  Serum-creatine-kinase in cases of stroke, head injury, and meningitis.

Authors:  H Dubo; D C Park; R J Pennington; R M Kalbag; J N Walton
Journal:  Lancet       Date:  1967-10-07       Impact factor: 79.321

3.  Clinical significance of serum creatine phosphokinase activity in cerebrovascular diseases.

Authors:  T Kotoku; H Kawakami; T Iwabuchi; T Sato; T Kutsuzawa
Journal:  Tohoku J Exp Med       Date:  1971-10       Impact factor: 1.848

4.  Serum and cerebrospinal fluid enzymes in cerebrovascular disease. Creatine phosphokinase, aldolase, and lactic dehydrogenase.

Authors:  A H Wolintz; L D Jacobs; N Christoff; M Solomon; N Chernik
Journal:  Arch Neurol       Date:  1969-01

5.  Assessment of outcome after severe brain damage.

Authors:  B Jennett; M Bond
Journal:  Lancet       Date:  1975-03-01       Impact factor: 79.321

6.  Levels of enolase and other enzymes in the cerebrospinal fluid as indices of pathological change.

Authors:  J A Royds; W R Timperley; C B Taylor
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-12       Impact factor: 10.154

7.  Brain creatine kinase in blood after acute brain injury.

Authors:  H Somer; M Kaste; H Troupp; A Konttinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-06       Impact factor: 10.154

8.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.

Authors:  A E Bolton; W M Hunter
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

9.  The effect of size, histologic elements, and water content on the visualization of cerebral infarcts.

Authors:  H Alcalá; M Gado; R M Torack
Journal:  Arch Neurol       Date:  1978-01

10.  Serum cardiac enzymes in stroke.

Authors:  J W Norris; V C Hachinski; M G Myers; J Callow; T Wong; R W Moore
Journal:  Stroke       Date:  1979 Sep-Oct       Impact factor: 7.914

View more
  16 in total

1.  S-100 protein in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: relation to functional outcome, late CT and SPECT changes, and signs of higher cortical dysfunction.

Authors:  H G Hårdemark; O Almqvist; T Johansson; S Påhlman; L Persson
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

2.  High neuron-specific enolase level of cerebrospinal fluid in the early stage of Creutzfeldt-Jakob disease.

Authors:  Y Wakayama; S Shibuya; J Kawase; F Sagawa; Y Hashizume
Journal:  Klin Wochenschr       Date:  1987-08-17

3.  The significance of neuron specific enolase levels in cerebrospinal fluid and serum after experimental traumatic brain damage.

Authors:  M Uzan; M Hanci; O Güzel; A C Sarioğlu; C Kuday; F Ozlen; M Y Kaynar
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

4.  Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults.

Authors:  B Sköldenberg; E Aurelius; A Hjalmarsson; F Sabri; M Forsgren; B Andersson; A Linde; O Strannegård; M Studahl; L Hagberg; L Rosengren
Journal:  J Neurol       Date:  2005-10-17       Impact factor: 4.849

5.  Elevated levels of the alpha subunit of GTP-binding protein Go in cerebrospinal fluid of patients with neurological disorders.

Authors:  T Murayama; A Takahashi; T Asano; K Kato
Journal:  J Mol Neurosci       Date:  1989       Impact factor: 3.444

6.  Cerebrospinal fluid neuron-specific enolase is decreased in multi-infarct dementia, but unchanged in Alzheimer's disease.

Authors:  R Sulkava; L Viinikka; T Erkinjuntti; R Roine
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-04       Impact factor: 10.154

7.  Behavioral and quantitative mitochondrial proteome analyses of the effects of simvastatin: implications for models of neural degeneration.

Authors:  Ilse S Pienaar; Timothy Schallert; Suzél Hattingh; William M U Daniels
Journal:  J Neural Transm (Vienna)       Date:  2009-06-06       Impact factor: 3.575

8.  A comprehensive study of repetitive transcranial magnetic stimulation in Parkinson's disease.

Authors:  Hideki Kimura; Masayuki Kurimura; Katsurou Kurokawa; Utako Nagaoka; Shigeki Arawaka; Manabu Wada; Toru Kawanami; Keiji Kurita; Takeo Kato
Journal:  ISRN Neurol       Date:  2011-08-08

9.  Serum levels of S100B and NSE proteins in Alzheimer's disease patients.

Authors:  Márcia L Chaves; Ana L Camozzato; Eduardo D Ferreira; Isabel Piazenski; Renata Kochhann; Oscar Dall'Igna; Guilherme S Mazzini; Diogo O Souza; Luis V Portela
Journal:  J Neuroinflammation       Date:  2010-01-27       Impact factor: 8.322

10.  Biomarkers of hypoxic-ischemic encephalopathy in newborns.

Authors:  Martha Douglas-Escobar; Michael D Weiss
Journal:  Front Neurol       Date:  2012-11-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.